PRKRA: A Protein Involved in Alzheimer's Disease (G8575)

Target Name: PRKRA

NCBI ID: G8575

PRKRA

Other Name(s): PACT | protein activator of interferon induced protein kinase EIF2AK2 | protein activator of the interferon-induced protein kinase | HSD14 | Protein kinase, interferon-inducible double-stranded RNA-dependent activator | PRKRA variant 1 | PKR-associating protein X | PRKRA variant 2 | Interferon-inducible double-stranded RNA-dependent protein kinase activator A (isoform 2) | protein kinase, interferon-inducible double-stranded RNA-dependent activator | Interferon-inducible double stranded RNA-dependent protein kinase activator A | PKR-associated protein X | Interferon-inducible double-stranded RNA-dependent protein kinase activator A (isoform 1) | DYT16 | Protein activator of interferon induced protein kinase EIF2AK2, transcript variant 2 | RAX | Protein activator of interferon induced protein kinase EIF2AK2, transcript variant 1 | Protein activator of the interferon-induced protein kinase | PRKRA_HUMAN | Interferon-inducible double-stranded RNA-dependent protein kinase activator A

PRKRA: A Protein Involved in Alzheimer's Disease

PRKRA (PACT) is a protein that is expressed in the brain and is known for its role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is derived from the science fiction novel \"The Postmortal\" by author Paul Park, and was named after the character of the same name in the book.

PRKRA is a transmembrane protein that is expressed in the brain and is involved in the regulation of several cellular processes, including the immune response, neurotransmitter signaling, and cell survival. It is made up of four transmembrane domains and a cytoplasmic tail, and is characterized by a number of unique features, including a predicted transmembrane potential (pTR) of -20 mV and a calculated pI of 4.9 nM.

One of the most interesting aspects of PRKRA is its role in the development and progression of Alzheimer's disease. Alzheimer's disease is a degenerative brain disorder that is characterized by the progressive loss of brain cells, including neurons and glial cells. The exact cause of Alzheimer's disease is not known, but it is thought to involve a combination of genetic and environmental factors.

Studies have shown that PRKRA is significantly reduced in the brains of people with Alzheimer's disease, and that it is involved in the development of the disease. Additionally, several studies have shown that inhibiting PRKRA can protect against the development of Alzheimer's disease in animal models.

In addition to its role in the development and progression of Alzheimer's disease, PRKRA is also a potential drug target. Several compounds have been shown to inhibit PRKRA, and further studies are being conducted to determine the effectiveness of these compounds in treating Alzheimer's disease.

One of the compounds that has been shown to inhibit PRKRA is Q2, a drug that is currently being tested for the treatment of Alzheimer's disease. Q2 works by inhibiting the activity of PRKRA and preventing the formation of neurofibrillary tangles, which are thought to contribute to the development of Alzheimer's disease.

Another compound that has been shown to inhibit PRKRA is Roscatorin, a drug that is being developed by Neurocrine Biosciences for the treatment of Alzheimer's disease. Roscatorin works by inhibiting the activity of PRKRA and increasing the levels of a protein called Tau in the brain.

In conclusion, PRKRA is a protein that is expressed in the brain and is involved in the regulation of several cellular processes. It is also known for its role in the development and progression of Alzheimer's disease. Several compounds have been shown to inhibit PRKRA, and further studies are being conducted to determine the effectiveness of these compounds in treating Alzheimer's disease.

Protein Name: Protein Activator Of Interferon Induced Protein Kinase EIF2AK2

Functions: Activates EIF2AK2/PKR in the absence of double-stranded RNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha and inhibition of translation and induction of apoptosis. Required for siRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required for processing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53 association and sumoylation and phosphorylation of p53/TP53 at 'Lys-386' at 'Ser-392' respectively and enhances its activity in a EIF2AK2/PKR-dependent manner (By similarity)

The "PRKRA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKRA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets